Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs

This publication has 31 references indexed in Scilit:

• Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
  Science, 2001
• Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
  New England Journal of Medicine, 2001
• Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
  New England Journal of Medicine, 2001
• Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR–ABL tyrosine kinase, CGP 57148
  Cell Death & Differentiation, 1998
• Inhibition of the ABL Kinase Activity Blocks the Proliferation of BCR/ABL+Leukemic Cells and Induces Apoptosis
  Blood Cells, Molecules, and Diseases, 1997
• Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells
  Nature Medicine, 1996
• Tyrosine Kinase Activity and Transformation Potency of bcr-abl Oncogene Products
  Science, 1990
• Induction of Chronic Myelogenous Leukemia in Mice by the P210 ^bcr/abl Gene of the Philadelphia Chromosome
  Science, 1990
• Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors
  Advances in Enzyme Regulation, 1984
• Effect of hydroxyurea on ribonucleotide reductase
  Biochemical and Biophysical Research Communications, 1968